Movement Alert｜Natera Falls 3.18% in Regular Trading, Profit-Taking Pressures Stock Despite Morgan Stanley Target Hike

Market Focus10-13 00:58

On October 13, Natera fell 3.18% in regular trading, trading at $388.28/share, with Turnover of $148 million.

The decline came despite Morgan Stanley's move to raise its price target on the stock to $435 from $355, maintaining an Overweight rating. The upward revision was primarily attributed to profit-taking pressures following a recent run-up in the share price. The company has made notable progress in the multi-cancer early detection space, with its assay granted FDA Breakthrough Device Designation, while its Signatera test received Japanese approval as a companion diagnostic for bladder cancer.

Within the Biotechnology sector where Natera belongs, the overall sector change is negative. Among individual stocks, Moderna fell 4.53%, AbbVie rose 1.44%, Gilead Sciences fell 0.68%, Amgen rose 0.19%, and First Tracks Biotherapeutics rose 8.45%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment